Vetter Pharma to Invest US$530 million (€480 Million) in Saarlouis, Germany
Introduction:
Vetter Pharma has announced plans to invest approximately US$530 million (€480 million) in the first phase of a new commercial manufacturing facility in Saarlouis, Germany.
Features:
The development involves the construction of a commercial manufacturing facility for sterile injectable medicines on an approximately 95-acre industrial site. Manufacturing operations will focus on aseptic production processes to support the large-scale manufacture of injectable drug products for global markets.
The project will be delivered through phased construction, beginning with an initial investment phase, and is supported by approved regional funding contributions. The facility will form part of a wider pharmaceutical manufacturing network across Europe and the United States, strengthening overall production capacity.
Construction is scheduled to begin in the second quarter of 2026, with operations expected to commence in 2031.
Specifications:
| Name | Vetter Pharma |
| Type | New Construction |
| Budget | US$530 million (€480 million) |
| Year | 2031 |
